
A phase III randomized, multicentre, double blind, active controlled trial to compare the efficacy and safety of two different anagrelide formulations in patients with essential thrombocythaemia – the TEAM ‐ ET 2·0 trial
Gisslinger, Heinz, Buxhofer‐Ausch, Veronika, Hodisch, Juri, Radinoff, Atanas, Karyagina, Elena, Kyrcz‐Krzemień, Slawomira, Abdulkadyrov, Kudrat, Gerbutavicius, Rolandas, Melikyan, Anait, Burgstaller,Journal:
British Journal of Haematology
DOI:
10.1111/bjh.15824
Date:
March, 2019
Fichier:
PDF, 349 KB
2019